Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

111In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib

Ingrid M.E. Desar, Alexander B. Stillebroer, Egbert Oosterwijk, William P.J. Leenders, Carla M.L. van Herpen, Winette T.A. van der Graaf, Otto C. Boerman, Peter F.A. Mulders and Wim J.G. Oyen
Journal of Nuclear Medicine November 2010, 51 (11) 1707-1715; DOI: https://doi.org/10.2967/jnumed.110.078030
Ingrid M.E. Desar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander B. Stillebroer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Egbert Oosterwijk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William P.J. Leenders
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carla M.L. van Herpen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Winette T.A. van der Graaf
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otto C. Boerman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter F.A. Mulders
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wim J.G. Oyen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 51 no. 11 1707-1715
DOI 
https://doi.org/10.2967/jnumed.110.078030
PubMed 
20956472

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication April 7, 2010
  • Accepted for publication August 3, 2010
  • Published online November 4, 2010.

Article Versions

  • previous version (October 18, 2010 - 06:08).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2010 by Society of Nuclear Medicine

Author Information

  1. Ingrid M.E. Desar*,1,
  2. Alexander B. Stillebroer*,2,3,
  3. Egbert Oosterwijk2,
  4. William P.J. Leenders4,
  5. Carla M.L. van Herpen1,
  6. Winette T.A. van der Graaf1,
  7. Otto C. Boerman3,
  8. Peter F.A. Mulders2 and
  9. Wim J.G. Oyen3
  1. 1Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  2. 2Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  3. 3Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; and
  4. 4Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  1. For correspondence: Ingrid M.E. Desar, Department of Medical Oncology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: i.desar{at}AIG.umcn.nl
View Full Text

Statistics from Altmetric.com

Cited By...

  • 40 Citations
  • 43 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • ImmunoPET: Concept, Design, and Applications
    Weijun Wei, Zachary T. Rosenkrans, Jianjun Liu, Gang Huang, Quan-Yong Luo, Weibo Cai
    Chemical Reviews 2020 120 8
  • Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
    Laetitia E. Lamberts, Maximillian Koch, Johannes S. de Jong, Arthur L.L. Adams, Jürgen Glatz, Mariëtte E.G. Kranendonk, Anton G.T. Terwisscha van Scheltinga, Liesbeth Jansen, Jakob de Vries, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Annelies Jorritsma-Smit, Matthijs D. Linssen, Esther de Boer, Bert van der Vegt, Wouter B. Nagengast, Sjoerd G. Elias, Sabrina Oliveira, Arjen J. Witkamp, Willem P.Th.M. Mali, Elsken Van der Wall, Paul J. van Diest, Elisabeth G.E. de Vries, Vasilis Ntziachristos, Gooitzen M. van Dam
    Clinical Cancer Research 2017 23 11
  • 89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry
    Sandra Heskamp, René Raavé, Otto Boerman, Mark Rijpkema, Victor Goncalves, Franck Denat
    Bioconjugate Chemistry 2017 28 9
  • Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients
    Arjan W. Griffioen, Laurie A. Mans, Annemarie M.A. de Graaf, Patrycja Nowak-Sliwinska, Céline L.M.M. de Hoog, Trees A.M. de Jong, Florry A. Vyth-Dreese, Judy R. van Beijnum, Axel Bex, Eric Jonasch
    Clinical Cancer Research 2012 18 14
  • 89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment
    Sjoukje F. Oosting, Adrienne H. Brouwers, Suzanne C. van Es, Wouter B. Nagengast, Thijs H. Oude Munnink, Marjolijn N. Lub-de Hooge, Harry Hollema, Johan R. de Jong, Igle J. de Jong, Sanne de Haas, Stefan J. Scherer, Wim J. Sluiter, Rudi A. Dierckx, Alfons H.H. Bongaerts, Jourik A. Gietema, Elisabeth G.E. de Vries
    Journal of Nuclear Medicine 2015 56 1
  • Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
    Laetitia E. Lamberts, Simon P. Williams, Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Jourik A. Gietema, Adrienne H. Brouwers, Elisabeth G.E. de Vries
    Journal of Clinical Oncology 2015 33 13
  • Molecular and functional imaging in cancer-targeted therapy: current applications and future directions
    Jing-Wen Bai, Si-Qi Qiu, Guo-Jun Zhang
    Signal Transduction and Targeted Therapy 2023 8 1
  • Indium-111–labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma
    Constantijn H.J. Muselaers, Otto C. Boerman, Egbert Oosterwijk, Johannes F. Langenhuijsen, Wim J.G. Oyen, Peter F.A. Mulders
    European Urology 2013 63 6
  • Phase 1 Radioimmunotherapy Study with Lutetium 177–labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma
    Alexander B. Stillebroer, Otto C. Boerman, Ingrid M.E. Desar, Marije J. Boers-Sonderen, Carla M.L. van Herpen, Johannes F. Langenhuijsen, Peter M. Smith-Jones, Egbert Oosterwijk, Wim J.G. Oyen, Peter F.A. Mulders
    European Urology 2013 64 3
  • Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond
    Javad Garousi, Anna Orlova, Fredrik Y. Frejd, Vladimir Tolmachev
    EJNMMI Radiopharmacy and Chemistry 2020 5 1

Article usage

Article usage: October 2010 to April 2025

AbstractFullPdf
Oct 2010101044
Nov 20102133299
Dec 2010402032
Jan 2011312928
Feb 2011371818
Mar 201118916
Apr 20111696
May 2011151924
Jun 2011572315
Jul 2011552722
Aug 2011661729
Sep 2011631830
Oct 2011671528
Nov 2011822823
Dec 2011711320
Jan 2012441825
Feb 2012511119
Mar 2012542216
Apr 2012612923
May 2012534025
Jun 2012354620
Jul 2012392532
Aug 2012352218
Sep 2012402017
Oct 2012251310
Nov 2012341618
Dec 2012401311
Jan 2013422416
Feb 2013572413
Mar 2013301525
Apr 2013541915
May 2013604520
Jun 2013181710
Jul 2013371111
Aug 201330710
Sep 201324711
Oct 201315135
Nov 2013221312
Dec 201313812
Jan 201410116
Feb 201420612
Mar 201436106
Apr 2014281032
May 20141768
Jun 2014231515
Jul 201414916
Aug 2014172212
Sep 2014132717
Oct 201423151
Nov 201415139
Dec 2014181613
Jan 2015282115
Feb 20151442
Mar 201538106
Apr 2015261812
May 201536106
Jun 2015231411
Jul 2015261410
Aug 20152396
Sep 20151823
Oct 2015768
Nov 2015341310
Dec 2015601915
Jan 201650179
Feb 201625415
Mar 201619715
Apr 201613413
May 201634212
Jun 20162268
Jul 2016181216
Aug 201613514
Sep 201619716
Oct 20162137
Nov 201615128
Dec 201691012
Jan 20171334
Feb 20171344
Mar 2017331312
Apr 2017792
May 201715105
Jun 20178142
Jul 2017621
Aug 2017171110
Sep 20172164
Oct 20171554
Nov 20172013
Dec 20171343
Jan 20181412
Feb 20181165
Mar 20181637
Apr 20181105
May 2018944
Jun 2018662
Aug 20181132
Sep 20181347
Oct 2018465
Nov 2018923
Dec 2018743
Jan 2019876
Feb 20198514
Mar 20191446
Apr 2019487
May 2019916
Jun 20199413
Jul 201910311
Aug 2019904
Sep 2019554
Oct 201913610
Nov 20191008
Dec 2019634
Jan 2020956
Feb 20201013
Mar 2020927
Apr 2020565
May 202010411
Jun 202014814
Jul 2020302
Aug 20208112
Sep 202011610
Oct 2020703
Nov 20201315
Dec 20207712
Jan 2021189
Feb 202131014
Mar 202141214
Apr 202131825
May 202131311
Jun 20212187
Jul 202141721
Aug 20214819
Sep 2021288
Oct 202111227
Nov 202111926
Dec 202121413
Jan 20222411
Feb 20220138
Mar 20222119
Apr 202261112
May 202221623
Jun 202211417
Jul 20221159
Aug 20220137
Sep 2022088
Oct 202221110
Nov 202211011
Dec 2022194
Jan 202393216
Feb 20231184
Mar 20230137
Apr 202311910
May 2023483
Jun 20234155
Jul 202311512
Aug 2023132
Sep 2023073
Oct 2023275
Nov 2023089
Dec 20230293
Jan 20241236
Feb 2024373
Mar 202411149
Apr 202441213
May 20240626
Jun 202443010
Jul 202451618
Aug 202432316
Sep 202431911
Oct 202452011
Nov 2024154
Dec 20241194
Jan 202502316
Feb 202517211
Mar 202533219
Apr 202512721
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 51 (11)
Journal of Nuclear Medicine
Vol. 51, Issue 11
November 1, 2010
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
111In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
111In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib
Ingrid M.E. Desar, Alexander B. Stillebroer, Egbert Oosterwijk, William P.J. Leenders, Carla M.L. van Herpen, Winette T.A. van der Graaf, Otto C. Boerman, Peter F.A. Mulders, Wim J.G. Oyen
Journal of Nuclear Medicine Nov 2010, 51 (11) 1707-1715; DOI: 10.2967/jnumed.110.078030

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
111In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib
Ingrid M.E. Desar, Alexander B. Stillebroer, Egbert Oosterwijk, William P.J. Leenders, Carla M.L. van Herpen, Winette T.A. van der Graaf, Otto C. Boerman, Peter F.A. Mulders, Wim J.G. Oyen
Journal of Nuclear Medicine Nov 2010, 51 (11) 1707-1715; DOI: 10.2967/jnumed.110.078030
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Immuno-PET in Pontine Glioma: More Than Meets the Eye?
  • Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
  • Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
  • 89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment
  • Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma
  • Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients
  • Drug-Based Optical Agents: Infiltrating Clinics at Lower Risk
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Is Long–Axial-Field-of-View PET/CT Cost-Effective? An International Health–Economic Analysis
  • Multicycle Dosimetric Behavior and Dose–Effect Relationships in [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy
Show more Clinical Investigation

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire